Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Little is known regarding the association of individual components of the metabolic syndrome
(MBS) and prothrombotic, inflammatory and preclinical cardiac structural and functional
markers in women with this syndrome. Less is known about adequate treatment as the
pathological mechanism of this syndrome is not well understood.
The purpose of this study is two fold;
1. To determine basic differences in biochemical and cardiovascular structural markers in
women with and those without MBS and their association with the individual components of
MBS.
2. To determine the impact of atorvastatin to lower the risk factors of Metabolic Syndrome.
Atorvastatin is one of the most effective drugs approved by the United States Food and
Drug Administration (FDA) for the treatment of high cholesterol. It belongs to a class
of drugs called statins and its role in primary prevention is still unclear. Thus this
population seems to be an ideal group that may benefit from this intervention.